CorMedix Inc. to Present at the Cantor Global Healthcare Conference
CORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
Buy Rating on Cormedix Affirmed Amidst DefenCath's Strong Market Entry and Growth Prospects
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
CorMedix Has Entered Into A Multi-Year Commercial Supply Contract With A Global Healthcare Company For The Supply Of DefenCath To Its Facilities In The U.S.
Express News | CorMedix Inc - Defencath Shipments Under Agreement to Begin in Q4
Too Tall : It has been there before.
If the next two quarters revenue grows this could be a Five Bagger!